Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 194

1.

A recent update of pharmacogenomics in drug-induced severe skin reactions.

Wei CY, Ko TM, Shen CY, Chen YT.

Drug Metab Pharmacokinet. 2012;27(1):132-41. Epub 2011 Nov 1. Review.

2.

Human leukocyte antigens and drug hypersensitivity.

Chung WH, Hung SI, Chen YT.

Curr Opin Allergy Clin Immunol. 2007 Aug;7(4):317-23. Review.

PMID:
17620823
3.

Pharmacogenetics of cutaneous adverse drug reactions.

Aihara M.

J Dermatol. 2011 Mar;38(3):246-54. doi: 10.1111/j.1346-8138.2010.01196.x. Review.

PMID:
21342226
4.

Recent advances in the genetics and immunology of Stevens-Johnson syndrome and toxic epidermal necrosis.

Chung WH, Hung SI.

J Dermatol Sci. 2012 Jun;66(3):190-6. doi: 10.1016/j.jdermsci.2012.04.002. Epub 2012 Apr 11. Review.

PMID:
22541332
5.

A study of HLA class I and class II 4-digit allele level in Stevens-Johnson syndrome and toxic epidermal necrolysis.

Cristallo AF, Schroeder J, Citterio A, Santori G, Ferrioli GM, Rossi U, Bertani G, Cassano S, Gottardi P, Ceschini N, Barocci F, Ribizzi G, Cutrupi V, Cairoli R, Rapisarda V, Pastorello EA, Barocci S.

Int J Immunogenet. 2011 Aug;38(4):303-9. doi: 10.1111/j.1744-313X.2011.01011.x. Epub 2011 May 4.

PMID:
21545408
6.

Toxic epidermal necrolysis and Stevens-Johnson syndrome.

Harr T, French LE.

Orphanet J Rare Dis. 2010 Dec 16;5:39. doi: 10.1186/1750-1172-5-39. Review.

7.

Genetic markers and danger signals in stevens-johnson syndrome and toxic epidermal necrolysis.

Chung WH, Hung SI.

Allergol Int. 2010 Dec;59(4):325-32. doi: 10.2332/allergolint.10-RAI-0261. Epub 2010 Oct 25. Review.

8.

HLA-B*1502 strongly predicts carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Thai patients with neuropathic pain.

Kulkantrakorn K, Tassaneeyakul W, Tiamkao S, Jantararoungtong T, Prabmechai N, Vannaprasaht S, Chumworathayi P, Chen P, Sritipsukho P.

Pain Pract. 2012 Mar;12(3):202-8. doi: 10.1111/j.1533-2500.2011.00479.x. Epub 2011 Jun 16.

PMID:
21676164
9.

Shared and restricted T-cell receptor use is crucial for carbamazepine-induced Stevens-Johnson syndrome.

Ko TM, Chung WH, Wei CY, Shih HY, Chen JK, Lin CH, Chen YT, Hung SI.

J Allergy Clin Immunol. 2011 Dec;128(6):1266-1276.e11. doi: 10.1016/j.jaci.2011.08.013. Epub 2011 Sep 14.

PMID:
21924464
10.

Severe cutaneous adverse reactions: acute generalized exanthematous pustulosis, toxic epidermal necrolysis and Stevens-Johnson syndrome.

Harr T, French LE.

Med Clin North Am. 2010 Jul;94(4):727-42, x. doi: 10.1016/j.mcna.2010.04.004. Review.

PMID:
20609860
11.

HLA-A31 strongly associates with carbamazepine-induced adverse drug reactions but not with carbamazepine-induced lymphocyte proliferation in a Japanese population.

Niihara H, Kakamu T, Fujita Y, Kaneko S, Morita E.

J Dermatol. 2012 Jul;39(7):594-601. doi: 10.1111/j.1346-8138.2011.01457.x. Epub 2011 Dec 29.

PMID:
22211527
12.

CD94/NKG2C is a killer effector molecule in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis.

Morel E, Escamochero S, Cabañas R, Díaz R, Fiandor A, Bellón T.

J Allergy Clin Immunol. 2010 Mar;125(3):703-10, 710.e1-710.e8. doi: 10.1016/j.jaci.2009.10.030. Epub 2010 Feb 4.

PMID:
20132973
13.

HLA class I markers in Japanese patients with carbamazepine-induced cutaneous adverse reactions.

Ikeda H, Takahashi Y, Yamazaki E, Fujiwara T, Kaniwa N, Saito Y, Aihara M, Kashiwagi M, Muramatsu M.

Epilepsia. 2010 Feb;51(2):297-300. doi: 10.1111/j.1528-1167.2009.02269.x. Epub 2009 Aug 19.

14.

Pharmacogenetic markers of severe cutaneous adverse drug reactions.

Borroni RG.

G Ital Dermatol Venereol. 2014 Apr;149(2):219-26. Review.

PMID:
24819643
15.

Association of HLA-B*1502 allele with carbamazepine-induced toxic epidermal necrolysis and Stevens-Johnson syndrome in the multi-ethnic Malaysian population.

Chang CC, Too CL, Murad S, Hussein SH.

Int J Dermatol. 2011 Feb;50(2):221-4. doi: 10.1111/j.1365-4632.2010.04745.x.

PMID:
21244392
16.

Association between HLA-B*1502 and carbamazepine-induced severe cutaneous adverse drug reactions in a Thai population.

Tassaneeyakul W, Tiamkao S, Jantararoungtong T, Chen P, Lin SY, Chen WH, Konyoung P, Khunarkornsiri U, Auvichayapat N, Pavakul K, Kulkantrakorn K, Choonhakarn C, Phonhiamhan S, Piyatrakul N, Aungaree T, Pongpakdee S, Yodnopaglaw P.

Epilepsia. 2010 May;51(5):926-30. doi: 10.1111/j.1528-1167.2010.02533.x. Epub 2010 Mar 19.

17.

[Exploratory study on biomarkers associated with severe cutaneous adverse reactions].

Kaniwa N.

Yakugaku Zasshi. 2011 Feb;131(2):255-61. Review. Japanese.

18.

Carbamazepine-induced severe cutaneous adverse reactions and HLA genotypes in Koreans.

Kim SH, Lee KW, Song WJ, Kim SH, Jee YK, Lee SM, Kang HR, Park HW, Cho SH, Park SH, Min KU, Chang YS; Adverse Drug Reaction Research Group in Korea.

Epilepsy Res. 2011 Nov;97(1-2):190-7. doi: 10.1016/j.eplepsyres.2011.08.010. Epub 2011 Sep 13.

PMID:
21917426
19.

Pharmacogenetics of toxic epidermal necrolysis.

Lee MT, Hung SI, Wei CY, Chen YT.

Expert Opin Pharmacother. 2010 Sep;11(13):2153-62. doi: 10.1517/14656566.2010.495120. Review.

PMID:
20536296
20.

Patch testing in severe cutaneous adverse drug reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis.

Wolkenstein P, Chosidow O, Fléchet ML, Robbiola O, Paul M, Dumé L, Revuz J, Roujeau JC.

Contact Dermatitis. 1996 Oct;35(4):234-6.

PMID:
8957644

Supplemental Content

Support Center